These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12479522)

  • 1. Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.
    Choi RK; Lee NH; Lim DS; Hong Sk; Hwang HK
    Mayo Clin Proc; 2002 Dec; 77(12):1340-3. PubMed ID: 12479522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
    Sitges M; Villa FP
    Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alveolar hemorrhage as a complication of treatment with abciximab.
    Kalra S; Bell MR; Rihal CS
    Chest; 2001 Jul; 120(1):126-31. PubMed ID: 11451827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary hemorrhage after abciximab. Risk factors and the role of protamine].
    Rodríguez-Gómez FJ; Sánchez A; Martínez FJ; Andreu J; Alvarez A; Pujol E
    Rev Esp Cardiol; 2005 Apr; 58(4):453-5. PubMed ID: 15847742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention.
    Conley M; Patino G; Romick B; Almaleh M; Campbell C; Hawkins K; Moore S; Allan P
    Can J Cardiol; 2008 Feb; 24(2):149-51. PubMed ID: 18273491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.
    Tan HC; Low A; Ng KS; Budiono B; Sutandar A; Chia BL; Lim YT
    Singapore Med J; 2002 Nov; 43(11):587-9. PubMed ID: 12680530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abciximab and fatal pulmonary hemorrhage.
    Usman MH; Shah MA; ul-Islam T; Adenwalla HN; Rahman F; Baqir M; Altaf M; Venkataraman R; Cherayil M; Berger S
    Heart Lung; 2006; 35(6):423-6. PubMed ID: 17137944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
    Dippel EJ; Kereiakes DJ; Tramuta DA; Broderick TM; Shimshak TM; Roth EM; Hattemer CR; Runyon JP; Whang DD; Schneider JF; Abbottsmith CW
    Catheter Cardiovasc Interv; 2001 Mar; 52(3):279-86. PubMed ID: 11246236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.